The company is trading down from yesterday’s close of 6.55. Company shares last traded at $5.95 impressively lower than the 50 day moving average which is $6.88 and which is significantly below the 200 day moving average of $8.53. The 50 day moving average was down by -13.52% and the 200 day average went down by -30.26%.
Traders are more bullish on shares of the company if you consider the decrease in short interest. The stock saw a fall in short interest of -5.02% as of the latest report on September 29, 2017. Short shares fell 49,051 over that period. Days to cover increased from 9.0 to 15.0 and the percentage of shorted shares is 0.05% as of September 29. Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. Its product portfolio includes MYALEPT for the treatment of generalized lipodystrophy; JUXTAPID for treating homozygous familial hypercholesterolemia (HoFH) in adults; and zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company also offers LOJUXTA (lomitapide) hard capsule for the treatment of HoFH in adults; and MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada..
As of the last earnings report the EPS was $-5.12 and is estimated to be $-1.66 for the current year with 18,648,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-1.27 and the next full year EPS is projected to be $-1.21.